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Background: Despite potential long-term benefits, bilateral internal thoracic artery
grafting in diabetics remains controversial because of the risk of sternal infection.
We sought to assess the short- and long-term outcome after left-sided bilateral
internal thoracic artery grafting and to determine the configuration of choice in
diabetic subsets.
Methods: Between 1996 and 2001, 515 diabetics underwent isolated left-sided
skeletonized bilateral internal thoracic artery grafting. The outcome of 468 consec-
utive oral-treated diabetics and 47 selective insulin-treated patients was analyzed.
Patients undergoing T-grafting were compared with those undergoing in situ bilat-
eral internal thoracic artery arrangements.
Results: The respective rates for early mortality and sternal infections were 2.4%
and 1.9% in oral-treated diabetics and 6.3% and 4.3% in insulin-treated diabetics.
Multivariate correlates of sternal infection were chronic lung disease (odds ratio,
10), obesity (odds ratio, 7), reoperation (odds ratio, 22), and a creatinine level of 2
mg/dL or more (odds ratio, 8). Five-year survival was 82%. The T-graft (n  437)
and in situ (n  162) subgroups had comparable baseline profiles. Freedom from
cardiac mortality at 6.5 years was 95.6% and 87.6% (P  .277), and freedom from
repeat revascularization was 91.5% and 92.7% (P  .860), respectively. The choice
of bilateral internal thoracic artery configuration did not appear as a correlate of
mortality, cardiac mortality, or major adverse cardiac events. Complementary
right-sided gastroepiploic artery (hazard ratio, 0.36) and sequential (hazard ratio,
0.55) grafting were identified as protective factors against the occurrence of major
adverse cardiac events.
Conclusions: Routine skeletonized bilateral internal thoracic artery grafting can be
implemented safely in oral-treated diabetics. This strategy is associated with a favorable
late cardiac outcome and is thus recommended. Both left-sided bilateral internal thoracic
artery configurations provide comparable short- and long-term outcomes.
Subgroup analysis of the Bypass Revascularization Investigation iden-tified coronary artery bypass grafting (CABG) as the preferred methodof myocardial revascularization in diabetics.1 These findings werecorroborated by subsequent trials.2-6 An increasing number of patientsundergoing CABG are diabetics.7 Nevertheless, reflecting acceleratedatherosclerosis, diabetic patients are at a higher risk for long-term
mortality and have an increased propensity for bypass graft failure in comparison to
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nondiabetics.6,8 Thereby, diabetic patients may benefit from
a CABG, which is most resistant to the enhanced athero-
sclerotic process.
The superiority of the internal thoracic artery (ITA) over
other conduits has been established. Comparative studies
have demonstrated improved resistance to the development
of atherosclerosis, intimal hyperplasia, and medial calcifi-
cation9,10 and maintained vasoreactive properties despite
long-term diabetes.11 From a clinical standpoint, ITA use
has been recognized as a strong predictor of survival in
diabetic patients undergoing myocardial revasculariza-
tion.1,3 Although left-sided bilateral ITA (BITA) grafting is
associated with improved survival, event-free survival, and
freedom from repeat revascularization in the general popu-
lation,12 the application of this strategy in diabetics remains
controversial because of the risk of sternal infection and
subsequent lethal mediastinitis.13 To date, analysis of small
datasets did not offer a clear mandate for routine BITA use
in diabetics, and its long-term benefits in this group remain
unclear.
Recently, skeletonized ITA harvesting14 and modifica-
tions in perioperative glucose management15 were shown to
attenuate the risk of sternal infection. Reduced sternal
devascularization was shown after skeletonized ITA mobi-
lization.16
This study was designed to evaluate the risk of routine
BITA grafting in diabetics. Secondary goals were to assess
the long-term outcome after this strategy and to determine
the left-sided BITA configuration of choice.
Methods
Patient Population
Between April 1996 and October 2001, 515 consecutive diabetic
patients underwent isolated CABG with skeletonized BITA. This
group comprised 30% of all BITA grafting performed during this
period. Included in the study were diabetic patients receiving
oral-agent or insulin treatment before the index operation. Diabet-
ics managed with diet only were excluded.
Since 1996, we have not declined the use of skeletonized BITA
in diabetic patients. All oral-treated diabetics have been regarded
as eligible for BITA grafting. Excluded were patients undergoing
emergency operations, patients with chronic obstructive pulmo-
nary disease (COPD; including chronic bronchitis, emphysema,
and bronchial asthma), and women with a body mass index (BMI)
of 30 kg/m2 or more. Diabetics with these associated conditions,
which are included in this report, were among the first enrollees
who were recruited before data on their risk appeared.14 These
guidelines were similar to those applied for BITA grafting in
nondiabetics during this time.17 Patients were excluded from BITA
grafting only when they were considered at high risk for sternal
infection (detailed criteria), irrespective of the patient’s cardiac or
other risk factors. Therefore, there was no selection bias in patient
allocation to this technique. Conversely, among insulin-treated
diabetics, BITA grafting was performed selectively; other than the
aforementioned criteria, this was primarily based on the surgeon’s
preference. Neurologically symptomatic patients or asymptomatic
patients aged 65 years or older were routinely screened by carotid
Doppler assays, and those who required carotid endarterectomy
were excluded.
Surgical Technique
Operations were performed through a midsternotomy by using
standard cardiopulmonary bypass or off-pump coronary artery
bypass (OPCAB). Myocardial preservation during CPB involved
intermittent, antegrade, or retrograde blood cardioplegia (30°C-
32°C). Coronary stabilization during OPCAB was facilitated by
use of CTS stabilizers (Curpentino, Calif) or the Octopus system
(Medtronic, Minneapolis, Minn). ITAs were mobilized as skele-
tonized vessels.17 In all cases, BITA were used to graft the left
coronary system, ie, the myocardial territory supplied by the left
anterior descending and circumflex arteries. Two arrangements
were implemented: (1) free right ITA attached proximally on the
left ITA in a T-graft configuration and (2) in situ BITA with an
anteaortic crossover right ITA.17 The choice of configuration was
determined by previously detailed technical considerations17 and
was irrespective of the diabetic status. In case supplemental grafts
to the right coronary system were necessary, the in situ right
gastroepiploic artery (GEA) or saphenous vein was used. The type
of conduit selected was based on the surgeon’s preference; how-
ever, use of the GEA required stenosis more than 70% of the target
vessel.
Preoperative and Postoperative Management
On admission, glucose levels were managed by continuing the
patient’s regimen with additional sliding-scale–guided intermittent
subcutaneous insulin injections aimed at achieving serum glucose
levels of 250 mg/dL or less. Postoperative treatment included
intravenously administered isosorbide dinitrate (4 to 20 mg/h) for
2 days, and patients who received GEA grafts were treated with
calcium channel blockers for 6 months. Glucose management was
initially aimed at blood glucose levels of 250 mg/dL or less by
using intermittent insulin injections and renewal of oral medication
by the second postoperative day. After February 2000, glucose
management was modified, and continuous intravenous insulin
was administered for 48 postoperative hours to achieve target
levels of 200 mg/dL or less.15 Postoperative angiography was
performed selectively only in symptomatic patients (return of
angina or undetermined chest pain) or in those with a positive
radionuclear scan.
Definitions and Data Collection
Patients’ data were analyzed according to the Society of Thoracic
Surgeons National Cardiac Surgery Database guidelines and def-
initions. Causes of death were classified as cardiac or noncardiac.
Cardiac mortality was defined as death occurring in relation to
myocardial infarction (MI), cardiac arrhythmia, out-of-hospital
sudden death, or deteriorating congestive heart failure. Undeter-
mined causes of death were regarded as cardiac. Major adverse
cardiac events (MACE) were defined as the occurrence of a
nonfatal MI, the need for repeat revascularization, or cardiac
mortality. Follow-up was obtained by a telephone questionnaire
and the national registry database.
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Data Analysis
Data are expressed as mean SD. The 2 test and Fisher exact test
were used to compare discrete variables. Actuarial survival and
event-free survival curves were obtained with the Kaplan-Meier
method. Statistical significance was calculated with the log-rank
test. Cox analysis was used to evaluate the influence of preoper-
ative and operative variables on late survival, freedom from car-
diac mortality, and freedom from MACE. Logistic regression was
used to evaluate the effect of preoperative and operative descrip-
tors on the occurrence of sternal infection. Results of logistic
regression are expressed as odds ratios (OR) with associated 95%
confidence intervals (CI) and P values. Results of Cox analysis are
expressed as hazard ratios (HR), 95% CI, and P values. All
analyses were performed with SPSS 9 software (SPSS Inc, Chi-
cago, Ill).
Results
The oral-treated diabetic group constituted 80% of all oral-
treated diabetics who underwent isolated CABG during this
period. Among the 515 study diabetics, there were 468
(90.9%) oral-treated patients and 47 (9.1%) insulin-treated
diabetics. Patients received 2 to 6 grafts (mean, 3), and the
ITA graft to patient ratio was 2.6 (overall, 1335 distal ITA
anastomoses were performed). Total arterial grafting was
achieved in 78% of operations. Details are listed in Table 1.
Early and late outcome are detailed in Table 2. The
observed 30-day mortality in the oral-treated group (2.4%)
was significantly lower than the predicted Euroscore (stan-
dard, 5.9%; logistic, 0.07; 95% CI, 0.061-0.077). Con-
versely, the 6.3% observed mortality for insulin-treated
patients was slightly higher than predicted (standard, 5.8%;
logistic, 0.06; 95% CI, 0.042-0.083). The major cause of
30-day mortality among oral-treated diabetics was cardiac
(58%), followed by neurologic, infectious, and renal causes
(14% each). Causes of death in the insulin-treated group
were cardiac, complicated renal failure, and sepsis (1 patient
each). The incidence of sternal infection was 1.9% and 4.3%
in the oral-treated and insulin-treated subgroups, respec-
tively.
Patients were compared on the basis of the configuration
of BITA grafting (T-graft vs in situ). The baseline profile
and operative data were similar, with the exception of more
grafts and sequential anastomoses in the T-graft subgroup and
more OPCAB performed in the in situ subgroup (Table 3).
Early results were comparable (Table 4).
Follow-up
Follow-up ranged from 6 to 79 months (average, 42 months)
and was ascertained for 98% of the patients. Late results are
listed in Tables 2 and 4. A total of 109 (8.2%) distal ITA
anastomoses were demonstrated angiographically (15 to 66
months after surgery; median: 40 months) with a patency
rate of 92%. All 27 (6.2%) T-anastomoses demonstrated
were patent. By 6.5 years, 22 (4.3%) repeat angioplasties
and 2 (0.4%) redo CABG operations had been performed
(range, 15 to 68 months after surgery; median, 41 months).
Eighteen of the 24 procedures were to non–ITA-grafted
vessels, ie, nongrafted native arteries or non-ITA conduits.
TABLE 1. Baseline characteristics and operative data
Factor
Oral-treated
(n  468)
(%)
Insulin-treated
(n  47)
(%)
Total
(n  515)
(%)
Age (y)* 66.4 9.3 64.4 9.6 66.2 9.3
Age 75 y 17.6 21.3 17.6
Female sex 30.1 38.3 30.9
Body mass index 30 kg/m2 7.7 12.8 8.2
Peripheral vascular disease 15 34 16.7
Hyperlipidemia 48.4 44.7 48.1
Chronic lung disease 6.2 2.1 5.8
Serum creatinine 2 mg/dL 3.8 8.5 4.3
Prior neurologic events 8.8 0 8
Acute MI 1 wk 17.9 6.4 16.9
Congestive heart failure 18.2 23.4 18.6
Ejection fraction 35% 8.3 8.5 8.3
Prior angioplasty 14.1 29.8 15.6
Left main disease 28.8 27.7 28.7
3-Vessel disease 80 91 81
2-Vessel disease 20 9 10
Intra-aortic balloon 3.4 2.1 3.3
Emergency surgery 7.1 2.1 6.6
Redo CABG 1.5 2.1 1.6
Mean grafts per patient* 3.1 0.84 2.7 0.72 3 0.83
Sequential grafts 51.5 34 49.9
T-grafts 68.6 63.8 68.3
Use of GEA 19.7 21.3 19.8
Use of saphenous vein 22.3 14.9 21.6
Bypass time (min)* 84 33 70 23 83 32
Clamp time (min)* 72 23 62 21 71 23
Off-pump 9.3 8.9 9.3
MI, Myocardial infarction; CABG, coronary artery bypass graft; GEA, gas-
troepiploic artery.
*Data are mean  SD.
TABLE 2. Early and late* results
Variable
Oral-treated
(n  468)
(%)
Insulin-treated
(n  47)
(%)
Total
(n  515)
(%)
30-d mortality 2.4 6.4 2.7
Q-wave MI 1.1 0 1
Neurologic complications 1.5 2.1 1.6
Deep sternal infection 1.9 4.3 2.1
Overall sternal complications 3.4 6.4 3.7
Late nonfatal MI 2.6 4.3 2.7
Repeat revascularization 4.1 10.6 4.7
MACE† 10.3 14.9 10.8
Late mortality 12.4 10.6 12.3
Late cardiac mortality 6 4.4 5.9
MI, Myocardial infarction; MACE, major adverse cardiac events.
*Late results were defined as events occuring between the 1st and 80th
postoperative month.
†Occurrence of 1 or more of the following: late nonfatal MI, reintervention,
or cardiac-related mortality.
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Five-year survival was 82% for the oral-treated group
and 84.7% for the selective insulin-treated group, respec-
tively (Kaplan-Meier). Freedom from cardiac mortality at 1,
5, and 6.5 years was 99.5%, 91.4%, and 90%, respectively
(Kaplan-Meier). At 6.5 years, freedom from nonfatal MI
and freedom from repeat revascularization was 94% and
93% for the oral-treated patients and 93% and 82% for
insulin-treated diabetics, respectively.
Comparison between the in situ and T-graft subgroups at
6.5 years showed comparable freedom from nonfatal MI
(96% and 92%, respectively; P  .514; log rank) and
freedom from repeat revascularization (91.5% and 92.7%; P
 .860; log rank). Correspondingly, there was no difference
in cardiac mortality (95.8% and 90%; P .277; log rank) or
MACE (86.2% and 80.5%; P  .531; log rank).
Analysis of Morbidity and Late Cardiac Outcome
Significant predictors of deep sternal infection were COPD
(P  .003; OR, 10.6), BMI greater than 30 kg/m2 (P 
.008; OR, 7.0), female sex (P .022; OR, 5.5), redo CABG
(P  .023; OR, 22.7), and a serum creatinine level of 2
mg/dL or more (P  .025; OR, 8.2). The risk of obese
women for the development of sternal infection was 22-fold
(P  .042; OR, 22).
Predictors of late mortality, late cardiac mortality, and
MACE are listed in Table 5. Sequential grafting (P  .047;
HR, 0.55) and the use of supplemental right-sided GEA (P
 .028; HR 0.36) were identified as protective factors
against the occurrence of MACE. Sequential grafting also
had a protective effect on cardiac mortality (P  .093; HR
0.49). The choice of left-sided BITA configuration (T-grafts
or in situ) was not identified as a correlate of survival, late
cardiac mortality, or the occurrence of MACE.
Discussion
The main finding of this study was that routine skeletonized
BITA grafting can be implemented safely in oral-treated
diabetics. This approach was associated with favorable late
cardiac outcomes. Both configurations of left-sided BITA
grafting—in situ and T-grafting—provided comparable
short- and long-term results.
Small datasets of diabetics undergoing BITA grafting did
not offer a clear mandate for routine use of this strategy.
This analysis of a large diabetic cohort attempted to resolve
this issue. Oral- and insulin-treated diabetics were analyzed
separately. Whereas the former group presented consecutive
patients with no selection bias, the use of BITA in insulin-
treated diabetics was selective. Nevertheless, these data are
presented because of their sparsity in the literature. The
observed 1.9% incidence of sternal infections among oral-
treated diabetics compares with that reported after single
ITA mobilization in this diabetic subset.1,18,19 Multivariate
analysis validated previous observations that identified
COPD and obesity (BMI30 kg/m2) as strong predictors of
sternal infection.14 The combination of being obese, dia-
betic, and female increased the risk by 22-fold. Severe renal
TABLE 3. Baseline characteristics and operative data: pa-
tients are grouped on the basis of the left-sided bilateral
internal thoracic artery configuration
Variable
In situ
(n  162)
(%)
T-graft
(n  437)
(%) P value
Age (y) 65 9 67 9 .143
Female sex 30.2 31.4 .791
BMI 30 kg/m2 7.4 8.6 .636
PVD 14.8 17.6 .436
Hyperlipidemia 52.8 46.4 .179
COPD 3.7 6.6 .185
Creatinine 2 mg/dL 2.5 5.2 .241
Neurologic events 6.8 8.4 .529
Acute MI 13 18.7 .106
CHF 19.8 17.6 .550
EF 35% 8 8.4 .899
Emergency operation 5.6 7.2 .488
Redo CABG 1.9 1.4 .713
Insulin treatment 10.5 8.6 .502
Grafts per patient 2.9 0.9 3.2 0.8 .0001
Sequential anastomoses 34.6 57 .0001
Supplemental GEA 17.3 21 .323
Supplemental SV 22.2 21.3 .819
Bypass time (min) 78 29 80 34 .494
Clamp time (min) 68 21 73 22 .189
Off-pump 21.6 3.5 .001
BMI, Body mass index; PVD, peripheral vascular disease; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; CHF, congestive
heart failure; EF, ejection fraction; CABG, coronary artery bypass grafting;
GEA, gastroepiploic artery; SV, saphenous vein.
TABLE 4. Early and late* results: patients are grouped on
the basis of the left-sided bilateral internal thoracic artery
configuration
Variable
In situ
(n  162)
(%)
T-graft
(n  437)
(%) P value
30-d mortality 3.1 2.6 .755
Q-wave MI 1.2 0.9 .655
Neurologic events 1.9 1.4 .714
Deep sternal infection 1.9 2.3 .999
Overall sternal infection 4.3 3.5 .632
Return of angina 6.2 8.7 .322
Late nonfatal MI 1.9 3.2 .564
Repeat revascularization 4.4 5 .771
Late cardiac mortality 3.3 6.9 .116
MACE† 10.5 15 .168
Late mortality 10.6 12.9 .168
MI, Myocardial infarction; MACE, major adverse cardiac events.
*Late results were defined as events occuring between the 1st and 80th
postoperative month.
†Occurrence of 1 or more of the following: late nonfatal MI, reintervention,
or cardiac-related mortality.
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dysfunction and redo CABG were further identified as cor-
relates of sternal infection. It is our recommendation, there-
fore, that BITA grafting, irrespective of the mobilization
technique, be avoided in these diabetic subsets. Time-frame
analysis further showed that the incidence during the last 2
years was lower than in the preceding time period (1.4% vs
2.4%, respectively). This may reflect the learning curve
associated with the skeletonization technique, the formation
of eligibility criteria along the study,14 and adoption of a
more vigilant policy of glucose control15 during this period.
Evidently, this 3-armed strategy is associated with repro-
ducible results.
The 30-day mortality (2.4%) among oral-treated diabet-
ics was significantly lower than the Euroscore-predicted
mortality and compares favorably with the 3.2% mortality
in the corresponding Society of Thoracic Surgeons database
oral-treated subgroup.20
It has been postulated that long-term cardiac protection is
provided only by arterial grafts, whereas venous conduits
undergo pathophysiologic and clinical deterioration that is
similar to that from native coronary disease.21 Recent inter-
est has focused on the use of arterial conduits in diabet-
ics5,19; however, because surgeons are reluctant to use
BITA in these patients, it may be that less-than-optimal
alternative arterial grafts are used. The only conduit found
to improve survival in diabetics is the ITA,1,3 and left-sided
BITA grafting is the only recognized grafting pattern asso-
ciated with improved survival in the general population.12
This study focuses on left-sided BITA grafting in diabetics.
Our results imply that this approach may confer cardiac
benefits in diabetics as well. Taking into account that the
ITA attrition rate is confined to the early postoperative
years,22 the 4.7% repeat revascularization rate at 6.5 years
seems favorable. Although angiograms were performed se-
lectively in prone patients (symptomatic patients or those
with positive radionuclear scan; see Methods), a 92% ITA
patency rate was shown. Most repeat revascularizations
were required because of non-ITA graft failure or progres-
sion of disease in nongrafted vessels. This may explain the
low rate of re-CABG (0.4%), because patients with a dura-
ble patent left-sided BITA retain a survival benefit from the
initial CABG and would have less of a benefit from reop-
eration. This should be viewed in the face of a recently
reported 11% mortality in re-CABG in diabetics.23 Further,
the observed results (Table 2) should be viewed in face of
the 11% repeat revascularizations at 7 years4 and 13% at 8
years6 reported with single ITA grafting or the 19% cardiac
mortality in similar diabetic cohorts.6 Nevertheless, because
this observational study does not include comparative data,
the question of whether BITA grafting confers superior
long-term outcome in comparison to other grafting strate-
gies remains to be answered.
An additional conduit is often required to graft the right
coronary territory when left-sided BITA is applied. In this
study, the GEA or saphenous vein was used for this pur-
pose. Complementary right-sided GEA was found by mul-
tivariate analysis to be associated with a reduced risk of
MACE. This benefit was not apparent in a previous study
conducted in the general population.24 Sequential grafting
also showed a protective tendency with regard to cardiac-
related mortality. The benefits conferred by sequential anas-
tomoses have been previously detailed.22,25
The preferred BITA configuration remains controversial.
Several clinical studies have demonstrated comparable re-
sults between in situ and T-grafts17,26; however, incidental
evidence suggest incomplete relief of ischemia after T-
grafting.27 It has been speculated that unique problems of
T-grafts, such as competitive flow or limited flow reserve,
might be exacerbated in diabetics secondary to enhanced
atherosclerotic processes9,10 or altered vasoreactivity.11
This study shows that the 2 techniques are comparable with
regard to short- and long-term outcome. Also, the choice of
BITA configuration was not identified as a correlate of
mortality, cardiac mortality, or MACE. Therefore, the
choice of technique should be primarily based on technical
considerations during the operation.16
Several limitations of this study need to be addressed. It
is a retrospective study, and a direct comparison with other
conduits would be required to determine the long-term
advantage of BITA in diabetic subsets. The small number of
TABLE 5. Cox analysis: independent risk factors for all-cause mortality, cardiac mortality, and MACE*
Variable
All cause mortality Cardiac mortality MACE
HR 95% CI P HR 95% CI P HR 95% CI P
Age 1.056 1.019-1.095 .003 1.047 0.995-1.102 .080 0.977 0.947-1.007 .129
COPD 2.249 0.972-5.202 .058 2.613 0.810-8.424 .108 2.059 0.846-5.010 .112
EF 35% 1.207 0.510-2.857 .669 2.573 0.939-7.051 .066 1.281 0.532-3.083 .580
LM disease 1.640 0.941-2.857 .081 1.993 0.860-4.617 .108 1.499 0.816-2.753 .192
Sequential grafting 0.825 0.470-1.448 .503 0.490 0.213-1.126 .093 0.552 0.307-0.993 .047
Use of GEA 0.608 0.274-1.349 .221 0.634 0.202-1.993 .436 0.364 0.148-0.896 .028
HR, Hazard ratio; CI, confidence interval; COPD, chronic pulmonary disease; EF, ejection fraction; LM, left main coronary artery; GEA, gastroepiploic artery.
*Occurrence of 1 or more of the following: late nonfatal myocardial infarction, reintervention, or cardiac-related mortality.
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insulin-treated patients and the low number of events negate
definite conclusions with regard to the feasibility of BITA
grafting in this subgroup.
In conclusion, routine skeletonized BITA grafting can be
performed safely in oral-treated diabetics. This strategy is
associated with favorable late cardiac outcome. Both left-
sided BITA configurations (in situ and T-grafting) provide
comparable short- and long-term outcome; therefore, the
choice of technique should be based on technical consider-
ations during the operation. Conclusions with regard to the
safety of BITA grafting in insulin-treated diabetics should
await further data.
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